<DOC>
	<DOCNO>NCT00541320</DOCNO>
	<brief_summary>This study design assess safety efficacy GW813893 prophylaxis VTE follow TKR provide evidence enable selection appropriate dose ( ) dose regimen GW813893 future investigation .</brief_summary>
	<brief_title>Phase IIa Venous Thromboembolism ( VTE ) Prevention Study In Total Knee Replacement ( TKR )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>2- ( 5-chlorothien-2-yl ) -N- ( 1- ( 1-methyl-2- ( morpholin-4-yl ) -2-oxoethyl ) -2-oxopyrrolidin-3-yl ) ethenesulfonamide</mesh_term>
	<criteria>Inclusion criterion : Patients schedule primary elective unilateral total knee arthroplasty . Exclusion criterion : Women surgically sterile postmenopausal Have contraindication contract venography Have know disorder associate increase risk bleed immobile 12 week surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anti-thrombolytic direct Factor Xa inhibitor</keyword>
</DOC>